Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from PureTech Health ( (GB:PRTC) ).
PureTech Health announced that the FDA has granted Fast Track designation to its monoclonal antibody, LYT-200, for treating acute myeloid leukemia (AML). This designation aims to expedite the development of treatments for serious conditions with unmet needs. LYT-200, which targets the oncogenic protein galectin-9, is currently in Phase 1/2 trials for AML and head and neck cancers, showing favorable safety profiles and initial anti-tumor activity. This milestone builds on previous recognitions, including Orphan Drug designation for AML, and highlights PureTech’s commitment to addressing urgent patient needs and enhancing its position in oncology.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicines to treat devastating diseases. The company has a robust pipeline created through its research and development efforts and collaborations with scientists, clinicians, and industry leaders. PureTech has developed 29 therapeutics and candidates, with three FDA-approved, and it advances these programs internally and through its Founded Entities.
YTD Price Performance: -6.79%
Average Trading Volume: 725,044
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £335.2M
Learn more about PRTC stock on TipRanks’ Stock Analysis page.
